Goldman Sachs
KALV

Goldman Sachs’s KalVista Pharmaceuticals KALV Stock Holding History

Goldman Sachs’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-243,600
Closed -$2.98M – 5730
2023
Q4 		$2.98M Buy
+243,600
New +$2.22M ﹤0.01% 3601

Other funds holding KALV

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Goldman Sachs's KALV Position: Q2 2026 in Review

Goldman Sachs sold out of KalVista Pharmaceuticals (KALV) in Q2 2026, closing a stake of 824,293 shares — an estimated $16.6M sold.

Goldman Sachs first reported a position in KALV in Q2 2015 and held it in 34 quarters. The position peaked at $21.9M in Q3 2025. 1 fund tracked by Wall St. Rank holds KALV as of Q2 2026.

  • Goldman Sachs reported no remaining KalVista Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Goldman Sachs sold 824,293 KalVista Pharmaceuticals shares in Q2 2026, an estimated $16.6M.
  • Goldman Sachs first reported a position in KalVista Pharmaceuticals in Q2 2015 and held it in 34 quarters.
  • Goldman Sachs's KalVista Pharmaceuticals position peaked at $21.9M in Q3 2025.
  • 1 fund tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.